Nov 2, 4:10 PM ET
Healthpeak Properties reported third quarter 2026 net income of $0.02 per share and diluted FFO as Adjusted of $0.44 per share. The company raised its full year 2026 FFO as Adjusted and same-store cash NOI guidance ranges while lowering its diluted EPS guidance due to acquisition-related depreciation. Shareholders also saw active leasing across outpatient medical and lab segments alongside strategic acquisitions.
- Diluted net income of $0.02 per share and diluted FFO as Adjusted of $0.44 per share for the third quarter of 2026.
- Raised full year 2026 diluted FFO as Adjusted per share guidance to a range of $1.76 to $1.78.
- Janus Living reported third quarter revenue of $268 million, up 78% compared to the prior year quarter.
- Net Debt to Adjusted EBITDAre was 4.7x for the quarter ended September 30, 2026.
Read the filing on SEC.gov ↗
Aug 4, 4:19 PM ET
Healthpeak reported second quarter 2026 results on August 4, 2026, with total revenues of $771.6 million, up from $694.3 million a year earlier, and diluted earnings of $0.08 per share, up from $0.05. The company raised its full-year 2026 diluted earnings and diluted FFO as Adjusted guidance by $0.02 per share at the midpoint, and its quarterly FFO as Adjusted per share was flat at $0.46.
- Q2 2026 diluted EPS was $0.08 versus $0.05 a year earlier; diluted FFO as Adjusted per share was $0.46, unchanged from the prior year.
- 2026 diluted EPS guidance is $0.48 to $0.52, up from $0.46 to $0.50; diluted FFO as Adjusted guidance is $1.73 to $1.77, up from $1.71 to $1.75.
- The Brookfield joint venture closed in July 2026 with proceeds of approximately $1.025 billion for a 49% interest in an 86-property outpatient medical portfolio.
- The board authorized a new $500 million share repurchase program and declared a third-quarter dividend totaling $0.305 per share.
Read the filing on SEC.gov ↗
May 5, 4:16 PM ET
Healthpeak reported first-quarter 2026 diluted EPS of $0.28, up from $0.06 a year earlier, while diluted Nareit FFO fell to $0.42 per share from $0.45. The company raised its full-year 2026 diluted EPS guidance to $0.46 to $0.50 from $0.34 to $0.38 and lowered its Nareit FFO guidance to $1.68 to $1.72 from $1.70 to $1.74, while raising FFO as Adjusted guidance and reaffirming same-store NOI growth.
- Q1 2026 diluted EPS $0.28 vs. $0.06 in Q1 2025; diluted Nareit FFO $0.42 vs. $0.45; diluted FFO as Adjusted $0.45 vs. $0.46.
- 2026 diluted EPS guidance raised to $0.46 to $0.50 from $0.34 to $0.38.
- 2026 Nareit FFO guidance lowered to $1.68 to $1.72 from $1.70 to $1.74; FFO as Adjusted guidance raised to $1.71 to $1.75 from $1.70 to $1.74.
- Janus Living IPO in March 2026 generated approximately $880 million of net proceeds; Healthpeak owns 81.6% of Janus Living.
Read the filing on SEC.gov ↗
Mar 23, 4:13 PM ET
On March 23, 2026, concurrent with the Janus Living initial public offering, Healthpeak and its subsidiaries amended three credit agreements, with lenders consenting to the IPO. The Healthpeak term loan was amended to add a $400.0 million senior unsecured delayed draw facility and raise maximum borrowing capacity from $1.5 billion to $2.0 billion, with $750.0 million of unused capacity after closing.
- New $400.0 million senior unsecured delayed draw term loan facility with a five-year stated maturity
- Healthpeak term loan maximum borrowing capacity raised from $1.5 billion to $2.0 billion
- Initial margin on new facility is 0.80% for Term SOFR and Daily SOFR loans, based on current debt ratings
- Revolver and Physicians Realty term loan amendments made no change to maturity, pricing or commitment amounts
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
